Biocytogen inks non-exclusive VHH antibody licensing deal with Qilu Pharma
Biocytogen Pharmaceuticals (Beijing) entered a non-exclusive licensing agreement with Qilu Pharmaceutical covering a fully human VHH antibody molecule.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, SSE: 688796; HKEX: 02315) today announced that it has entered into a non-exclusive licensing agreement with Qilu Pharmaceutical Co., Ltd. (“Qilu Pharmaceutical”) for a fully human VHH antibody molecule.
Under the agreement, Biocytogen wi…